Documente Academic
Documente Profesional
Documente Cultură
esis promoted by chronic inflammation is B lymphocyte depen- pabilities of B cells and CD19-positive plasma
dent. Cancer Cell 2005;7:411-23. cells.1,2 Through this mechanism, CTL019 may
3. Ammirante M, Luo J-L, Grivennikov S, Nedospasov S, Karin
M. B-cell-derived lymphotoxin promotes castration-resistant have clinical usefulness in other cancers that do
prostate cancer. Nature 2010;464:302-5. not express CD19, particularly in combination
4. Balkwill F, Montfort A, Capasso M. B regulatory cells in with other immunotherapies.
cancer. Trends Immunol 2013;34:169-73.
5. Hansmann L, Blum L, Ju C-H, Liedtke M, Robinson WH, AlfredL. Garfall, M.D.
Davis MM. Mass cytometry analysis shows that a novel memory
phenotype B cell is expanded in multiple myeloma. Cancer Im-
EdwardA. Stadtmauer, M.D.
munol Res 2015;3:650-60. CarlH. June, M.D.
DOI: 10.1056/NEJMc1512760 Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
cjune@exchange.upenn.edu
The authors reply: In reply to Shimabukuro- Since publication of his article, Dr. Garfall reports receiving
Vornhagen and colleagues: the mechanism of ac- consulting fees from Novartis. No further potential conflict of
interest relevant to this letter was reported.
tion underlying the efficacy of CTL019 in the
case of multiple myeloma we reported remains 1. Affara NI, Ruffell B, Medler TR, et al. B cells regulate mac-
uncertain. In our discussion, we acknowledged rophage phenotype and response to chemotherapy in squamous
carcinomas. Cancer Cell 2014;25:809-21.
the possibility that elimination of non-neoplastic 2. Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosup-
B cells by CTL019 might be at least partially re- pressive plasma cells impede T-cell-dependent immunogenic
sponsible for its therapeutic activity, and we cited chemotherapy. Nature 2015;521:94-8.
prior studies showing the tumor-promoting ca- DOI: 10.1056/NEJMc1512760
text of this letter at NEJM.org). Using a differ- (mothers who were 27 to 29 years of age) before
ence-in-differences analysis, we compared a and after the policy was implemented. As shown
treatment population (mothers who were 19 to in Figure 1 and the regression analysis in Table
25 years of age) with a control population S1 in the Supplementary Appendix, the young-
A Private Insurance for Age 1925 Yr B Private Insurance for Age 2729 Yr
53.5
26.5
53.0
26.0
Percentage
Percentage
25.5 52.5
25.0 52.0
C Medicaid Payment for Age 1925 Yr D Medicaid Payment for Age 2729 Yr
66 39.5
65 39.0
Percentage
Percentage
38.5
64
38.0
63
Staggered 37.5 Staggered
implemen- implemen-
62 tation 37.0 tation
period period
0 0.0
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Jan. Jan. Jan. Jan. Jan. Jan. Jan. Jan. Jan. Jan.
Month of Birth Month of Birth
4.8
4.5
Percentage
Percentage
4.6
4.4
4.0
Staggered 4.2 Staggered
implemen- implemen-
3.5 tation 4.0 tation
period period
0.0 0.0
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Jan. Jan. Jan. Jan. Jan. Jan. Jan. Jan. Jan. Jan.
Month of Birth Month of Birth
G Other Payment for Age 1925 Yr H Other Payment for Age 2729 Yr
7.0 5.8
6.8 5.6
Percentage
Percentage
6.6 5.4
6.4 5.2
adult provision led to an increase of 2.5 percent- ever, childbirth tends to be the most costly part
age points (95% confidence interval [CI], 1.6 to of pregnancy and payment sources for childbirth
3.4) in private-insurance reimbursement a probably are similar to payment sources for con-
9.9% relative increase from baseline. Medicaid current care.
payments decreased by 2.1 percentage points Yaa AkosaAntwi, Ph.D.
(95% CI, 3.0 to 1.3), and self-payments decreased Indiana UniversityPurdue University Indianapolis
by 0.3 percentage points (95% CI, 0.5 to 0.2). Indianapolis, IN
Most of the changes involved payments for yakosaan@iupui.edu